Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 3, 2026Future Medicinal Chemistry

Five-membered heterocyclic scaffolds emerge as promising VEGFR-2 inhibitors to overcome resistance and improve safety.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Long-term efficacy of first-generation VEGFR-2 inhibitors is limited by off-target toxicities, suboptimal pharmacokinetics, and drug resistance, driving the need for next-generation inhibitors.

Design

Review

Key result

Five-membered heterocyclic scaffolds represent promising novel VEGFR-2 inhibitors engineered to overcome resistance and improve safety compared to first-generation agents.

Authors

MKMohamed M. KhalifaISIbtehal Nasser SalmanRJReyadh Jassem

Discussion

Loading...

Member takes

Overview

Supports scaffold optimization for selective VEGFR-2 inhibition; leaves open clinical translation in resistant cancers.

Key Points

  • To review recent advances in the rational design, synthesis, and biological assessment of five-membered heterocyclic VEGFR-2 inhibitors aimed at overcoming resistance and toxicity.
  • Systematically analyzed recent progress in developing five-membered heterocyclic scaffolds, including thiadiazole, oxazole, thiazole, pyrrole, pyrazole, and imidazole derivatives.
  • Evaluated molecular hybridization strategies targeting hinge-binding regions, DFG motifs, and allosteric pockets, along with detailed structure-activity relationships.
  • Five-membered heterocyclic scaffolds offer adaptable structural frameworks for designing highly selective VEGFR-2 inhibitors with enhanced binding interactions.
  • Optimizing substituent variations on these heterocycles improves pharmacokinetics, safety margins, and potency against drug-resistant tumor pathways.

Structured PICO

I
Intervention
Five-membered heterocyclic scaffolds (thiadiazol, oxazole, thiazole, pyrrole, pyrazole, and imidazole-based inhibitors) as novel VEGFR-2 inhibitors

This review highlights recent advances in the design and synthesis of five-membered heterocyclic scaffolds as next-generation VEGFR-2 inhibitors to overcome limitations of first-generation drugs.

Cite This Study

Khalifa et al. (2026) conducted a review in Cancer. Five-membered heterocyclic scaffolds (VEGFR-2 inhibitors) was evaluated. Five-membered heterocyclic scaffolds represent promising novel VEGFR-2 inhibitors engineered to overcome resistance and improve safety compared to first-generation agents.

synapsesocial.com/papers/6a993600636c6408cfa7ebcbhttps://doi.org/10.1080/17568919.2026.2726194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Six‐Membered Heterocycles as VEGFR‐2 Kinase Inhibitors: A Structural and Therapeutic Review2026
  2. 2Development and assessment of novel pyrazole–thiadiazol hybrid derivatives as VEGFR-2 inhibitors: design, synthesis, anticancer activity evaluation, molecular docking, and molecular dynamics simulation2024 · 2 citations
  3. 3Recent Advancements in the Development of Heterocyclic Scaffolds asPotential Anti-cancer Agents Targeting EGFR and VEGFR-22026
  4. 4Sulfonamide Derivatives as Potent VEGFR-2 Inhibitors: Advances and Therapeutic Perspectives: A Comprehensive Review2025
  5. 5VEGFR‐2 Targeting Oxadiazole‐Pyrazole Hybrids: Synthesis, Molecular Docking, and Cytotoxic Evaluation in Cancer Cells2026